Palmatine chloride

Synonyms: 盐酸巴马汀
Palmatine chloride 是一种具有口服活性的不可逆 IDO-1 抑制剂,对 HEK 293-hIDO-1 和 rhIDO-1 的 IC50 分别为 3 μM 和 157 μM,同时也能非竞争性抑制西尼罗病毒 (WNV) NS2B-NS3 蛋白酶(IC50 为 96 μM),并具有抗癌、抗炎、神经保护、抗细菌和抗病毒活性。
产品编号: MS-Y99042 纯度: 99.87% CAS No.: 10605-02-4 分子式: C21H22ClNO4 分子量: 387.86
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
250mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
询价
10g
询价
询价

产品描述

Palmatine chloride 是一种具有口服活性的不可逆 IDO-1 抑制剂,对 HEK 293-hIDO-1 和 rhIDO-1 的 IC50 分别为 3 μM 和 157 μM,同时也能非竞争性抑制西尼罗病毒 (WNV) NS2B-NS3 蛋白酶(IC50 为 96 μM),并具有抗癌、抗炎、神经保护、抗细菌和抗病毒活性。

生物实验数据

生物活性 Palmatine chloride is an orally active, irreversible IDO-1 inhibitor with IC50 values of 3 μM and 157 μM for HEK 293-hIDO-1 and rhIDO-1, respectively, and it also non-competitively inhibits West Nile virus (WNV) NS2B-NS3 protease with an IC50 of 96 μM, exhibiting anticancer, anti-inflammatory, neuroprotective, antibacterial, and antiviral activities.
IC50 & Target IDO1:157 μM (rhIDO-1), WNV NS2B-NS3:96 μM, IDO1:3 μM (HEK 293-hIDO-1)
体外研究
(In Vitro)

Palmatine (0-100 μM;42 h) 抑制 WNV,其 EC50 值为 3.6 μM,并分别以 EC50 值为 26.4 μM 和 7.3 μM 降低 DENV-2 和 YFV 的病毒滴度。
Palmatine (0-1128 μM;24-72 h) 抑制结肠癌细胞的增殖。
Palmatine (0-704 μM;24 h) 降低 AURKA 蛋白水平,诱导结肠癌细胞发生 G2/M 期阻滞,并通过线粒体相关途径诱导细胞凋亡。

Cell Proliferation Assay

Cell Line: HCT-116, SW480, HT-29
Concentration: 0, 88, 176, 352, and 704 μM (HCT-116, SW480); 0, 141, 282, 564, and 1128 μM (HT-29)
Incubation Time: 24, 48 and 72 h
Result: Decreased cell viability in a dose-dependent manner.

Western Blot Analysis

Cell Line: HCT-116, SW480, HT-29
Concentration: 100 nM for HCT-116, 500 nM for SW480 and HT-29
Incubation Time: 24 h
Result: Promoted the expression of apoptosis markers such as P53 / P73, Caspase3, and Caspase9. Reduced AURKA protein levels. Increased cyt. c in the cytoplasm while reduced Bcl2 and Bcl-xl in a dose-dependent manner.

Cell Cycle Analysis

Cell Line: HCT-116, SW480
Concentration: 88, 176, 352 and 704 μM
Incubation Time: 24 h
Result: Induced G2/M phase arrest in a dose-dependent manner.

Apoptosis Analysis

Cell Line: HCT-116, SW480
Concentration: 88, 176, 352 and 704 μM
Incubation Time: 24 h
Result: Induced apoptosis in a dose-dependent manner.
体内研究
(In Vivo)

Palmatine (50 或 100 mg/kg;口服;每日一次,持续 7 天) 改善了由右旋糖酐硫酸钠 (DSS) 诱导的结肠炎,并防止炎症细胞浸润。
Palmatine (0-200 mg/kg;腹腔注射;单次给药) 减轻了由 D-半乳糖胺//Lipopolysaccharides (MS-X54539) 诱导的小鼠暴发性肝衰竭。
Palmatine (0-1 mg/kg;腹腔注射;每日一次,持续 10 天) 在小鼠中显示出增强记忆的作用。
Palmatine (33.75-135 mg/kg;口服;每日一次,持续 26 天) 可有效抑制小鼠体内 HCT-116 异种移植瘤的生长。

Animal Model: DSS- induced Colitis BALB/c mice model (8-week-old)
Dosage: 50 or 100 mg/kg
Administration: Orally, daily, for 7 days
Result: Ameliorated DSS-induced colitis and prevented infiltration of inflammatory cells; remarkably extended the colon length; significantly suppressed the colonic MPO activity. Decreased the levels of colonic inflammatory cytokines (TNF-α, IFN-γ, IL-1β, IL-6, IL-4 and IL-10); Protected mucosal integrity by modulating TJs protein and apoptosis proteins; Restored DSS-induced decreases of TJ protein ZO-1, ZO-2 and claudin-1; Reduced Bax expression and enhanced Bcl-2 expression at the dose of 100 mg/kg, prevented epithelial apoptosis and improved intestinal integrity. Prevented DSS-induced changes of gut microbiota in colitis mice.
Animal Model: Male ICR mice (20–22 g), D-galactosamine/lipopolysaccharide (GalN/LPS)-induced fulminant hepatic failure model
Dosage: 25, 50, 100, or 200 mg/kg
Administration: Intraperitoneal injection, 1 h before the GalN/LPS treatment
Result: Attenuated the mortality and serum aminotransferase activities increased by GalN/LPS. Prevented the increase of serum TNF-α and augmented that of serum IL-10. Decreased the TNF-a mRNA expression and increased the IL-10 mRNA expression. Attenuated the apoptosis of hepatocytes.
Animal Model: Swiss young male albino mice, with Scopolamine (MS-P46812)- and diazepam-induced amnesia model
Dosage: 0.1, 0.5, 1 mg/kg
Administration: Intraperitoneal injection, 10 days
Result: Significantly improved learning and memory of mice at 0.5 and 1 mg/kg and did not show any significant effect on locomotor activity of the mice. Significantly reversed scopolamine- and diazepam-induced amnesia in mice. Significantly reduced brain acetylcholinesterase activity of mice.
Animal Model: BALB/c-nude mice, HCT-116 xenograft model
Dosage: 33.75, 67.5 and 135 mg/kg
Administration: Oral administration, once a day for 26 days
Result: The tumor volume and weight of the treatment group were significantly reduced.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 387.86
分子式 C21H22ClNO4
CAS No. 10605-02-4
别名 盐酸巴马汀

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 4.17 mg/mL (10.75 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1.00 mg/mL (2.58 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 32 mg/mL (82.50 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 5 mg/mL (12.89 mM; 超声助溶)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / DMSO1 mM2.5782 mL12.8912 mL25.7825 mL64.4562 mL
5 mM0.5156 mL2.5782 mL5.1565 mL12.8912 mL
10 mM0.2578 mL1.2891 mL2.5782 mL6.4456 mL
DMSO15 mM0.1719 mL0.8594 mL1.7188 mL4.2971 mL
20 mM0.1289 mL0.6446 mL1.2891 mL3.2228 mL
25 mM0.1031 mL0.5156 mL1.0313 mL2.5782 mL
30 mM0.0859 mL0.4297 mL0.8594 mL2.1485 mL
40 mM0.0645 mL0.3223 mL0.6446 mL1.6114 mL
50 mM0.0516 mL0.2578 mL0.5156 mL1.2891 mL
60 mM0.0430 mL0.2149 mL0.4297 mL1.0743 mL
80 mM0.0322 mL0.1611 mL0.3223 mL0.8057 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础